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Abstract
A double-blind, randomized clinical trial was conducted to determine the effect of consumption of supplemental whey
protein (WP), soy protein (SP), and an isoenergetic amountof carbohydrate (CHO) on body weight and compositionin free-
living overweight and obese but otherwise healthy participants. Ninety overweight and obese participants were randomly
assigned to 1 of 3 treatment groups for 23 wk: 1)W P ;2) SP (each providing ;56 g/d of protein and 1670 kJ/d); or 3)a n
isoenergetic amount of CHO. Supplements were consumed as a beverage twice daily. Participants were provided no
dietary advice and continued to consume their free-choice diets. Participants’ body weight and composition data were
obtained monthly. Dietary intake was determined by 24-h dietary recalls collected every 10 d. After 23 wk, body weight
and composition did not differ between the groups consuming the SP and WP or between SP and CHO; however, body
weightandfatmassof thegroupconsuming theWPwerelowerby1.8 kg(P, 0.006)and2.3 kg(P ,0.005),respectively,
thanthegroupconsumingCHO.Leanbodymassdidnotdifferamonganyof thegroups.Waistcircumference wassmaller
in the participants consuming WP than in the other groups (P , 0.05). Fasting ghrelin was lower in participants consuming
WP compared with SP or CHO. Through yet-unknown mechanisms, different sources of dietary protein may differentially
facilitate weight loss and affect body composition. Dietary recommendations, especially those that emphasize the role of
dietary protein in facilitating weight change, should also address the demonstrated clinical potential of supplemental
WP. J. Nutr. 141: 1489–1494, 2011.
Introduction
Dietary approaches for controlling unhealthy weight gain are
becoming increasingly important and using dietary manipula-
tions to control hunger is 1 potential means to control energy
intake. Many investigations of dietary manipulations to mod-
ulate body weight, especially those with higher protein diets,
include energy restriction during or subsequent to the dietary
modulation (1–13). Results from these interventions suggest that
body weight loss is greater while consuming higher protein diets
and satiety may be a key factor (14). However, because these
participants were in an energy deﬁcit, it is difﬁcult to separate
the effects of the catabolic state from those of the dietary
macronutrients.
In short-term studies with subjective assessment of hunger and
satiety, dietary protein has been shown to be more satiating than
isoenergetic intake of fat and carbohydrate (9,15–17). Although
results from these short-term studies can provide insight into
energy intake regulation, it is unclear what effect any short-term
response in food intake will have on long-term energy intake and
body weight regulation, especially in a noncatabolic state. Thus,
longer term dietary interventions with body weight or composi-
tion as outcomes may answer these questions.
Not all longer term dietary interventions of restricted energy
intake concomitant with increased protein intake have demon-
strated that these diets improve body weight or composition (18–
20). In most interventions, the source of dietary protein is
typically not described (3,5,7,10,11,19) or is from mixed sources
(6,8,12,13). Protein source may be important to consider in
understanding the success or failure of these interventions. For
example, in a study of overweight and obese men fed isoenergetic
diets, animal protein (pork) increased energy expenditure com-
pared with a vegetable (soy) protein (21). Wistar rats (10 wk old)
fed a high-protein diet with whey protein concentrate had a 4%
reduction in weight gain and reduced visceral and subcutaneous
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(22). These results suggest that there might be differential effects
among protein sources on energy intake or body weight regula-
tion. However, the rat data are from young, growing animals
whose physiological state might be much different from an adult
human. Likewise, human studies investigating differentsources of
protein andbodyweightandcompositionhaveeitherbeenofvery
short duration or conducted with energy restriction, thus con-
founding the interpretation of the results.
The primary objective of the present study was to determine
the effects of added supplemental protein to the habitual diet of
free-living overweight and obese adults, without energy restric-
tion, on body weight and composition. A secondary objective
was to determine whether there are differential effects between
protein sources on body weight and composition in a longer
term intervention. Whey and soy are both readily available
proteins and both have been implicated in regulating food
intake. We hypothesized that supplementation of overweight
and obese free-livingindividuals with wheyprotein(WP)
3would
decrease body weight and fat compared with individuals
supplemented with isonitrogenous soy protein (SP) or isoener-
getic carbohydrate (CHO) and that insulin, insulin-like growth
factor (IGF), ghrelin, and thyroid hormones would be affected
by protein source.
Methods
Study design
A double-blind, randomized clinical trial was conducted to determine
the effects of supplemental WP and SP and an isoenergetic amount of
CHO on body weight and composition in free-living overweight and
obese but otherwise healthy individuals for 23 wk. In addition, plasma
glucose, insulin, ghrelin, IGF, and serum thyroid hormones were
determined to evaluate metabolic and hormonal changes. Because
dietary intake and physical activity can alter body weight and compo-
sition, these factors were monitored at frequent intervals throughout the
intervention.
Participants. Ninety participants were recruited and randomly assigned
(stratiﬁed by sex, BMI, and age) to 1 of 3 groups: WP, SP, or an
isoenergetic amount of CHO (maltodextrin). The sample size was
selected to determine a 3% change in body weight (P , 0.05) with 90%
power among each treatment comparison (23–25). Participants were
stratiﬁed to treatment based on gender and BMI.
Inclusion into the study was for nonsmokers having a BMI (in kg/m
2)
.28 and ,38, fasting glucose ,7 mmol/L, blood pressure ,160/100
mm Hg, and total cholesterol ,6.2 mmol/L. Exclusion criteria included:
history or presence of kidney, gastrointestinal, liver, or thyroid disease,
gout, certain cancers, or type 2 diabetes; recent weight loss; recently
following a high-protein diet or using antiobesity medications or
supplements; and consuming a WP or SP supplement. Medical history,
routine blood chemistry indexes, complete blood count, urine analysis,
and a physical examination were used to evaluate each participant’s
eligibility for inclusion in the study. The protocol and consent form were
reviewed and approved by the Institutional Review Board of Medstar
Research Institute. Participants provided written informed consent and
received $800 for successful participation.
Intervention. Each treatment supplement was speciﬁcally formulated
and manufactured for this study (Innovative Food Processors) and was
provided in 3 ﬂavors in serving sizes of 52 g/packet (Table 1). The source
of WP was WP concentrate-80, the source of SP was an isoﬂavone-free
SP isolate (Prolisse, Cargill), and the source of CHO was maltodextrin
(Maltrin M180, Grain Processing). The WP concentrate-80 was from a
cheese-derived source and was not hydrolyzed. An isoﬂavone-free SP
isolate was selected to minimize the impact of nonprotein compounds
and focus on the biological effects of the macronutrient component.
Participants were instructed to consume 1 pack immediately prior to,
during, or immediately after breakfast and dinner. The total amount of
energy from the treatments was 1670 kJ/d. Participants were provided
with information on the energycontent of the products but with minimal
instruction from a registered dietician on how to make dietary alter-
ations to incorporate these products. Participants completed a question-
naire each day to record the time the treatment was consumed and
general health questions. Participants were provided a daily vitamin and
mineral supplement (Os-cal Ultra; GlaxoSmithKline Consumer Health-
care) to standardize supplemental calcium intake.
Compliance. Compliance was determined by counting the number of
packets distributed and recounting those not consumed and by measur-
ing para amino benzoic acid (PABA) in urine samples collected at
random, unannounced times monthly to determine whether PABA was
present in the urine. The PABAwas added to each treatment packet at a
concentration of 0.24 mg/kJ. The half-life of PABA is very short (,18 h);
it was decided that $3 of 5 urine samples without PABA would be a
criterion for noncompliance.
Dietary intake assessment. Usual dietary intake was assessed every
10 d using the USDA’s Automated Multiple-Pass Method (26). All 24-h
recalls were completed in person and were performed in the morning on
all days of the week.
TABLE 1 Chemical composition of the carbohydrate
(CHO), whey protein (WP), and soy protein (SP)
treatment supplements
1,2
CHO WP SP
g/packet
Weight 52 51 52
Protein 0.6 27.5 28.1
Moisture 1.7 2.2 1.8
Fat, acid hydrolysis 0.7 1.5 2.0
Ash 1.0 1.4 2.7
Total carbohydrate 48.0 18.4 17.4
Calcium 0.20 0.22 0.25
para-Aminobenzoic acid 0.2 0.2 0.2
mg/packet
L-Aspartic acid 36.4 3060 3200
L-Threonine 18.2 1850 945
L-Serine 23.4 1570 1480
L-Glutamic acid 62.4 4860 5340
L-Proline 26.0 1690 1000
L-Glycine 18.2 541 1150
L-Alanine 15.6 1370 1150
L-Cystine 10.4 694 319
L-Valine 20.8 1590 1310
L-Methionine 10.4 592 354
L-Isoleucine 13.0 1730 1310
L-Leucine 26.0 3060 2190
L-Tyrosine 26.0 820 997
L-Phenylalanine 18.2 918 1440
L-Histidine 10.4 530 716
L-Lysine 15.6 2470 1690
L-Arginine 26.0 726 2070
L-Tryptophan 10.4 607 400
1 Participants consumed 2 treatment packets/d, 1 with breakfast and the evening
meal, along with their typical diet.
2 Chemical composition was determined by Covance Laboratories.
3 Abbreviations used: CHO, carbohydrate; IGF, insulin-like growth factor; IGFBP,
insulin-like growth factor binding protein; PABA, para amino benzoic acid; SP, soy
protein; T3, triiodothyronine; T4, thyroxine; VAS, visual analogue scale; WP, whey
protein.
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assessed daily for 23 wk, before consumption of the treatment and
evening meal by means of 4 visual analogue scale (VAS) questions that
described hunger, desire to eat, the amount of food that could be eaten,
and stomach fullness. The VAS were all 100 mm in length and were
anchored at either end with terms indicating opposite descriptors (27).
Physical activity assessment. Physical activity was measured semi-
monthly with an activity monitor (accelerometer) for 7 consecutive days
(Actigraph MTI AM 7164–1.2; Manufacturing Technology). Activity
monitors were attached to a snuggly ﬁtting belt worn around the waist
(28).
Body weight and composition. Prior to the start of the intervention and
then monthly, body weight and composition were measured by air-
displacement plethysmography (BodPod 2000A, BodPod 2.0 Software,
Life Measurement). Measurements were made according to the manufac-
turer’s guidelines. Participants fasted for at least 12 h before the measure-
ments and refrained from exercise. Thoracic lung volume was automatically
estimated. The Siri formula was used to calculate percent body fat (29).
Anthropometry. Prior to the start of the intervention and then monthly,
waistcircumferencewasmeasuredabovetherightiliumonthemidaxillary
line. Hip circumference was measured at the level of the maximum
extension of the buttocks. Measurements were made with a ﬁberglass tape
measure by 2 trained individuals following a written protocol with almost
90% of the measures performed by 1 of the 2 individuals.
Biological sample collection and analysis. Five times during the
study (before the intervention and after 12, 16, 20, and 23 wk of the
intervention), blood was collected after a 12-h fast. Plasma and serum
samples were collected after centrifugation and frozen at 2808C. Plasma
insulin concentrations were measured by ELISA (LINCOplex; LINCO
Research). Plasma glucose concentrations were measured enzymatically
(Smith-Kline Beecham Laboratories). Plasma concentrations of total
ghrelinwere measured byRIA (LINCOResearch).PlasmaIGF-IandIGF
binding protein (IGFBP)-3 concentrations were measured by ELISA
(R&D Systems). Plasma IGFBP-1 concentration was measured by ELISA
(LINCOplex; LINCO Research). Serum free thyroxine (T4) concentra-
tions and triiodothyronine (T3) uptake were analyzed with an enzyme-
multiplied immunoassay (Siemens; Centaur). Urine samples were
collected monthly. Urine was collected and frozen at 2808C until
analysis for PABA by HPLC (30–32).
Statistical analyses. Prior to ANOVA, each variable was evaluated
for normality and homogeneity of variance within groups. A log
transformation was performed for glucose and insulin so that these
data would not violate the homogeneity of variance assumption needed
to perform the ANOVA. Repeated-measures analyses (MIXED proce-
dure in SAS; SAS Institute) were used to evaluate changes over time.
The model included treatment, sex, time, 2-way interactions, and the
3-way interaction as ﬁxed effects. Pretreatment values were included as
covariates. Results were interpreted ﬁrst through the 3-way interac-
tion. If this interaction was signiﬁcant (P , 0.05), within time,
treatment effects were evaluated. If this interaction was not signiﬁcant,
the 2-way interactions were investigated. Within-time and within-sex
treatment effects were investigated. If no interactions were signiﬁcant,
t h em a i ne f f e c to ft r e a t m e n tw a se v a l u a t e d .I ft h et r e a t m e n te f f e c tw a s
signiﬁcant for any of the interactions or main effect evaluations, the
outcome for WP was compared with the CHO and SP values by using
the slice option to compare the least-squares means. Values reported
are means 6 SE.
Results
Participants and compliance. Seventy-three participants com-
pleted the intervention. Participant characteristics prior to the
start of the intervention (i.e. baseline) of those who completed
the entire protocol are presented in Table 2.
The mean number of supplement packets consumed over the
intervention was 2 per day, which was the prescribed amount.
However, PABA analysis of urine samples revealed 2 partici-
pants with undetectable PABA concentrations in 4 of 5 random
samples. Their data were excluded from all the analyses.
At breakfast time, most packets were consumed immediately
before or during the meal (44 and 41%, respectively) and fewer
wereconsumedimmediatelyafterthemeal(15%).Atdinnertime,
over one-half of the packets (52%) were consumed immediately
prior to the meal. The remainder dinner time packets were con-
sumed with the meal (20%) or immediately after the meal (28%).
Dietary intake. Dietary data are reported from 1060 dietary
recalls for 73 participants who completed the study. Mean
energy intake (including supplements) was 9060 6 560, 9140 6
510, and 9490 6 460 kJ/d for the CHO, WP, and SP groups,
respectively, and did not differ among treatment groups. Mean
protein intake was 76 6 3, 131 6 6, and 135 6 3 g/d for the
CHO, WP, and SP treatment groups, respectively. Mean percent
of energy intake from protein was 14 6 1, 24 6 2, and 24 6 2%
for the CHO, WP, and SP treatment groups, respectively. Mean
percent of energy intake from CHO was 58 6 2, 49 6 2, and
48 6 1% for the CHO, WP, and SP treatment groups,
respectively. The percentages of energy intake from fat were
28 6 2, 27 6 2, and 28 6 1% for the CHO, WP, and SP
treatment groups, respectively. Protein intakes were 1.4 g/kg of
body weight for the protein treatments and 0.8 g/kg of body
weight for the CHO treatment groups. Energy and macronutri-
ent intakes were higher for men than for women (P , 0.0001),
with no detectable effect of treatment on changes in energy,
protein, carbohydrate, or fat intake during the course of the
intervention. Between the initial and ﬁnal recall, there was a
decrease in carbohydrate intake in the group consuming the WP
supplement (P , 0.04).
Subjective satiety. VAS questions were used to evaluate the
subjective satiety responses of the participants before the
evening meal for 23 wk. The dietary treatments did not affect
hunger (P = 0.11), desire to eat (P = 0.11), prospective
consumption (P = 0.38), or stomach fullness (P = 0.62). No
signiﬁcant treatment 3 sex or treatment 3 time interactions
TABLE 2 Baseline characteristics of the overweight or
obese adult men and women who completed the
study protocol
1
Treatment Age Height Weight BMI n
y m kg kg/m
2
Women
CHO 50 6 10 1.6 6 0.0 84.0 6 9.3 31.2 6 2.8 13
WP 45 6 9 1.7 6 0.1 87.3 6 11.7 31.4 6 2.4 13
SP 53 6 9 1.7 6 0.1 86.5 6 9.2 30.8 6 2.3 13
Men
CHO 51 6 7 1.8 6 0.1 99.7 6 13.1 30.9 6 2.2 12
WP 55 6 7 1.8 6 0.0 95.3 6 6.4 30.5 6 1.9 10
SP 54 6 9 1.8 6 0.1 102.7 6 11.8 31.1 6 2.4 12
All
CHO 51 6 9 1.7 6 0.1 91.5 6 13.7 31.1 6 2.5 25
WP 49 6 9 1.7 6 0.1 90.8 6 10.4 31.0 6 2.2 23
SP 53 6 9 1.7 6 0.1 90.3 6 13.2 30.9 6 2.3 25
1 All values are means 6 SEM.
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inﬂuenced by sex or time (data not shown).
Physical activity. Physical activity did not differ between
treatment groups during the intervention period. Time of use
compliance of the monitors was .72%, with an mean wear of
17.4 6 2.6 h/d.
Body weight and composition. There were no differences
between treatment groups at baseline. A signiﬁcant interaction
existed between treatment and time; i.e. at the last measurement
time, the treatment means were different. At the end of the
intervention (after 23 wk), body weight of the group consuming
WP was 1.8 kg (2%) lower than that of the group consuming the
CHO treatment (P , 0.006) (Fig. 1A). Body weight did not
differ between the groups consuming SP and WP (0.9-kg
difference) or between the groups consuming SP and CHO
(0.9-kg difference). The treatment 3 sex interaction was not
signiﬁcant, indicating that the effect of treatment was not
different for men and women.
At the end of the intervention, body fat mass was 2.3 kg
lower in the group consuming the WP than in the group
consuming the CHO treatment (P , 0.005) (Fig. 1B). Body fat
mass of the group consuming SP was not different from that of
the group consuming the WP (1.1-kg difference), nor was it
signiﬁcantly different from the group consuming the CHO
treatment (1.2-kg difference). Lean body mass did not signiﬁ-
cantly differ among groups.
Anthropometry. There was no effect of treatment on waist
circumference before the last measurement. At the last measure-
ment time, waist circumference was 2.4 cm lower in the group
supplemented with WP than in the other 2 groups (Fig. 1C). The
effect of treatment was not different for men and women. Hip
circumference was not affected by treatment.
Biological samples. Fastingbloodglucoseconcentrationswere
unaffected by treatment; however, circulating insulin concentra-
tions were lower for participants consuming the whey and SP
treatments than for participants consuming the CHO treatments
(Table 3). There was no effect of treatment over time and the
effect of treatment was similar for both genders. Participants
consuming WP had lower ghrelin concentrations compared with
participants consuming the SP (P = 0.04) and CHO (P = 0.007)
treatments. Participants consuming the SP compared with CHO
treatment showed no treatment effects on ghrelin (P = 0.31).
Circulating IGF-I concentrations were higher in the group
consuming the SP supplement than in the groups supplemented
with WP or CHO, whereas IGFBP-3 concentrations were lower
in the group supplemented with WP than in the other 2 groups.
The IGFBP-1 concentration was not affected by treatment. T3
uptake was lower in the group supplemented with WP compared
with the group supplemented with SP; the group supplemented
with CHO did not differ from either protein group. Free T4
concentrations were lower in the groups supplemented with WP
and CHO than in the group supplemented with SP.
Discussion
This randomized, controlled clinical trial evaluated the effects of
supplementationwithWP,SP,oranisoenergeticamountofCHO
on body weight and composition in free-living overweight and
obese adults. At the end of the intervention, in the group
consuming supplemental WP compared with those consuming
supplemental CHO, there was a 1.8-kg difference in body mass
and a 2.3-kg difference in fat mass, with the CHO-supplemented
group being heavier than the protein-supplemented group. By
contrast,inthegroupconsumingsupplementalSPcomparedwith
thegroupconsumingsupplementalCHO,therewasnodifference
inbodymassorcomposition.Similarly,thegroupsconsumingthe
2 protein sources did not differ. Based on the length of the
treatmentandthedailyenergyprovidedfromthesupplement,we
would estimate that weight gain would exceed ~10 kg without
any compensation for the additional energy of the supplement.
Given the observed changes in weight, it appears that the energy
compensationoccurredforalltreatments.Thedifferenceinbody
weight and composition at the end of the intervention likely is
related to better compensation among the group consuming the
whey treatment compared with the CHO treatment. These
differences among treatments in body weight and composition
may be a result of subtle effects of CHO and protein on satiety.
Changesinenergyintakeintherangeofonly170–210kJ/dcould
FIGURE 1 Effect of supplemental carbohydrate (CHO), whey
protein (WP), and soy protein (SP) on body mass (A), fat mass (B),
and waist circumference (C) in overweight or obese adult men and
women. All values are least squares means 6 SEM, n = 73 (39
women, 34 men); n = 25 (CHO), 23 (WP), or 25 (SP). Means without a
common letter differ at the final measure, P , 0.05.
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this 23-wk intervention. These changes are so subtle that they
may not be detectible with the 24-h recall methodology. Addi-
tionally, consuming WP resulted in a signiﬁcantly smaller waist
circumference compared with the group consuming supplemen-
tal CHO. This ﬁnding is important, because the amount of intra-
abdominal adipose tissue is more signiﬁcantly correlated with
metabolic complications in obese individuals than is subcutane-
ous fat (33,34). During energy restriction, higher protein diets
consumed ad libitum facilitate weight loss, and improved satiety
isapresumedcontributingmechanism(14).Inthisstudyinwhich
energy restriction was not part of the intervention, changes in
bodyweightandcompositionweresmallbutneverthelesssuggest
that habitual consumption of supplemental protein may result in
improved body composition and incremental, but ultimately
signiﬁcant, weight loss. These data suggest that supplemental
dietary protein may reduce the risk of unhealthy weight gain
observed in many populations (i.e. 500–1000 g/y).
Although there were no differences among treatments with
respect to total (background diet + treatment) energy intake,
there was a decrease in the CHO intake of the background diet
between the initial and ﬁnal dietary recall in the participants
consuming the WP treatment. Consumption of supplemental
WP decreased concentrations of the orexigenic peptide ghrelin.
Ghrelin may serve as a hunger signal; it strongly increases food
intake in both animals and humans (35). In 1 study (36), there
was a decrease in the ghrelin concentration at 2 and 3 h
following acute ingestion of 55 g of whey or casein compared
with ingestion of 56 g of glucose or lactose. These results are
similar to our ﬁndings from samples collected after a 12-h fast.
In a second study, Bowen et al. (37) found a decrease in ghrelin
after ingestion of 50 g of soy, whey, or gluten protein compared
with glucose. However, in contrast to our ﬁnding, they did not
detect a difference among the protein sources. Study design
differences could account for the observed differences in
response; our observations are from samples collected after a
12-h fast and longer intervention, whereas Bowen et al. (37)
collected samples 2 or 3 h after ingestion of the foods, without
prior exposure. Further, protein consumption may reduce body
fat by stimulating the release of hormones affecting metabolic
rate. Thyroid hormone concentrations (T3 and T4) can increase
in participants consuming a high-protein diet compared with a
high-carbohydrate diet (38). Protein source did affect free T4
and T3 uptake concentrations; however, consuming SP increased
these concentrations more than did consuming WP. Further
research is required to gain a better understanding of the long-
term effects of differing protein sources on thyroid function.
Strengths and limitations of the study design warrant
consideration. Based on the number of participants who
completed the intervention, this study was well powered to
detect a small change in body weight. To better ensure
participant compliance with treatment (beyond measuring
disappearance of packets), we qualitatively measured urinary
excretion of an internal treatment marker at random time
points during the study. Assessment of dietary intake and
physical activity was performed on a regular and frequent
schedule. To assess dietary intake throughout the study, we
used a method that is designed to estimate current dietary
intake and strives to minimize the problem of misreporting
(39). However, this methodology is not sensitive enough to
detect the subtle changes in energy intake that take place to
result in the small yet signiﬁcant differences in weight seen in
this study (1.8 kg between WP and CHO groups). This study
did not include a placebo control group (no intervention) to
maintain a double-blind standard. Protein and carbohydrate
were selected for the intervention, because they both provide
similar metabolizable energy intake for a given mass. In this
intervention, participants were instructed to consume their
product immediately before, after, or during their meal. Much
previous research has used macronutrient interventions as a
preload to a meal. Preloading participants might have resulted
in greater treatment differences.
This intervention study reported on the effects of long-term
consumption of supplemental WP, SP, and CHO in a free-living
overweight and obese population without imposed energy
restriction. However, most studies examining the effects of
increased dietary protein have used mixed sources of proteins
(dairy, vegetable, meat, and soy) in conjunction with weight loss;
therefore, future research should target whether speciﬁc dietary
proteins may elicit beneﬁcial effects on body composition during
energy restriction. Future research should also target the dose of
speciﬁc proteins necessary for beneﬁcial effects on weight and
body composition and the interaction of dose and time needed to
observe any effects.
In conclusion, this study suggests that after 6 mo of
supplementation, there was a difference in body weight and
fat mass between overweight and obese adults who consumed
supplemental WP compared with those who consumed isoener-
getic supplemental CHO. The difference in body weight was
associated with a decrease in fat without an effect on lean mass.
Supplemental SP compared with CHO did not alter body weight
or composition, nor were there differences in body weight or
composition between soy and WP sources. Although there were
differences in food intake between males and females, the effects
of the intervention were consistent between males and females.
Short-term weight loss requires energy restriction and higher
protein diets may assist in this acute weight reduction; however,
protein supplementation, particularly WP, in overweight and
obese individuals may assist in long-term maintenance of body
weight without energy restriction.
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TABLE 3 Glucoregulatory biomarkers, insulin growth
factors, and thyroid function after consumption of
the carbohydrate (CHO), whey protein (WP), or
soy protein (SP) supplement in overweight or
obese adult men and women
1,2
Treatment
CHO WP SP
Glucose, log(mmol/L) 0.255 6 0.001 0.255 6 0.001 0.255 6 0.001
Insulin, log(pmol/L) 18.3 6 0.3
b 16.3 6 0.6
a 17.2 6 0.3
a
Ghrelin, ng/L 870 6 23
b 752 6 36
a 837 6 23
b
IGF-I, mg/L 77.8 6 1.4
a 81.5 6 2.1
a 87.0 6 1.3
b
IGFBP-1, ng/L 721 6 6 717 6 11 719 6 6
IGFBP-3, mg/L 1.98 6 0.03
b 1.82 6 0.05
a 2.04 6 0.03
b
T3 uptake, % 31.4 6 0.4
ab 30.9 6 0.5
a 32.5 6 0.4
b
Free T4, pmol/L 14.1 6 0.1
a 13.7 6 0.1
a 14.5 6 0.3
b
1 All values are least squares means 6 SEM, n = 73 (39 women, 34 men). Means
without a common letter differ.
2 Plasma glucose, insulin, ghrelin, IGF-I, IGFBP-1, IGFBP-3, and serum T3 uptake and
T4.
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